JP5934093B2 - 子宮内膜がんのマーカー - Google Patents
子宮内膜がんのマーカー Download PDFInfo
- Publication number
- JP5934093B2 JP5934093B2 JP2012520964A JP2012520964A JP5934093B2 JP 5934093 B2 JP5934093 B2 JP 5934093B2 JP 2012520964 A JP2012520964 A JP 2012520964A JP 2012520964 A JP2012520964 A JP 2012520964A JP 5934093 B2 JP5934093 B2 JP 5934093B2
- Authority
- JP
- Japan
- Prior art keywords
- endometrial cancer
- biomarkers
- level
- p4hb
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010014733 Endometrial cancer Diseases 0.000 title claims description 651
- 206010014759 Endometrial neoplasm Diseases 0.000 title claims description 650
- 239000000090 biomarker Substances 0.000 claims description 510
- 239000000523 sample Substances 0.000 claims description 445
- 101001072202 Homo sapiens Protein disulfide-isomerase Proteins 0.000 claims description 257
- 102100036352 Protein disulfide-isomerase Human genes 0.000 claims description 257
- 229920002791 poly-4-hydroxybutyrate Polymers 0.000 claims description 257
- 101100508538 Homo sapiens IKBKE gene Proteins 0.000 claims description 226
- 102100021857 Inhibitor of nuclear factor kappa-B kinase subunit epsilon Human genes 0.000 claims description 226
- 101710102635 GEM-interacting protein Proteins 0.000 claims description 219
- 102100034265 GEM-interacting protein Human genes 0.000 claims description 219
- 230000001965 increasing effect Effects 0.000 claims description 183
- 102100024784 Suppressor of cytokine signaling 2 Human genes 0.000 claims description 164
- 101000687808 Homo sapiens Suppressor of cytokine signaling 2 Proteins 0.000 claims description 160
- 238000000034 method Methods 0.000 claims description 158
- 102100028067 EGF-containing fibulin-like extracellular matrix protein 2 Human genes 0.000 claims description 145
- 101001060248 Homo sapiens EGF-containing fibulin-like extracellular matrix protein 2 Proteins 0.000 claims description 145
- 206010028980 Neoplasm Diseases 0.000 claims description 132
- 101710131668 Epithelial discoidin domain-containing receptor 1 Proteins 0.000 claims description 123
- 102100036725 Epithelial discoidin domain-containing receptor 1 Human genes 0.000 claims description 123
- 102100037789 FAST kinase domain-containing protein 1, mitochondrial Human genes 0.000 claims description 119
- 101000878541 Homo sapiens FAST kinase domain-containing protein 1, mitochondrial Proteins 0.000 claims description 119
- 239000012530 fluid Substances 0.000 claims description 115
- 102100035218 Epidermal growth factor receptor kinase substrate 8-like protein 2 Human genes 0.000 claims description 113
- 101000876686 Homo sapiens Epidermal growth factor receptor kinase substrate 8-like protein 2 Proteins 0.000 claims description 113
- 101000616738 Homo sapiens NAD-dependent protein deacetylase sirtuin-6 Proteins 0.000 claims description 113
- 102100021840 NAD-dependent protein deacetylase sirtuin-6 Human genes 0.000 claims description 113
- 101000731078 Homo sapiens Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Proteins 0.000 claims description 110
- 102100032391 Phosphorylase b kinase gamma catalytic chain, liver/testis isoform Human genes 0.000 claims description 110
- 230000014509 gene expression Effects 0.000 claims description 108
- 101001098179 Homo sapiens P2X purinoceptor 4 Proteins 0.000 claims description 99
- 102100037601 P2X purinoceptor 4 Human genes 0.000 claims description 99
- 108020004999 messenger RNA Proteins 0.000 claims description 96
- 108090000623 proteins and genes Proteins 0.000 claims description 93
- 102100039217 3-ketoacyl-CoA thiolase, peroxisomal Human genes 0.000 claims description 85
- 101000670146 Homo sapiens 3-ketoacyl-CoA thiolase, peroxisomal Proteins 0.000 claims description 85
- 101001122747 Homo sapiens Protein phosphatase 1 regulatory subunit 16A Proteins 0.000 claims description 85
- 102100028722 Protein phosphatase 1 regulatory subunit 16A Human genes 0.000 claims description 85
- 101001064427 Homo sapiens Liprin-beta-2 Proteins 0.000 claims description 81
- 102100031981 Liprin-beta-2 Human genes 0.000 claims description 81
- 102100033473 Cingulin Human genes 0.000 claims description 79
- 101000785517 Homo sapiens Tight junction protein ZO-3 Proteins 0.000 claims description 78
- 102100026640 Tight junction protein ZO-3 Human genes 0.000 claims description 78
- 102100040322 E3 ubiquitin-protein ligase RNF183 Human genes 0.000 claims description 75
- 101001104297 Homo sapiens E3 ubiquitin-protein ligase RNF183 Proteins 0.000 claims description 75
- 101000712974 Homo sapiens Ras association domain-containing protein 7 Proteins 0.000 claims description 75
- 102100033241 Ras association domain-containing protein 7 Human genes 0.000 claims description 75
- 201000011510 cancer Diseases 0.000 claims description 54
- 238000000338 in vitro Methods 0.000 claims description 49
- 239000003550 marker Substances 0.000 claims description 43
- -1 P HK G2 Proteins 0.000 claims description 42
- 230000000295 complement effect Effects 0.000 claims description 42
- 239000002299 complementary DNA Substances 0.000 claims description 41
- 238000003757 reverse transcription PCR Methods 0.000 claims description 38
- 210000002966 serum Anatomy 0.000 claims description 26
- 210000004369 blood Anatomy 0.000 claims description 25
- 239000008280 blood Substances 0.000 claims description 25
- 230000002357 endometrial effect Effects 0.000 claims description 21
- 102000039446 nucleic acids Human genes 0.000 claims description 19
- 108020004707 nucleic acids Proteins 0.000 claims description 19
- 150000007523 nucleic acids Chemical class 0.000 claims description 19
- 208000024891 symptom Diseases 0.000 claims description 17
- 238000001514 detection method Methods 0.000 claims description 13
- 238000003753 real-time PCR Methods 0.000 claims description 13
- 230000007423 decrease Effects 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 8
- 230000015556 catabolic process Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000006731 degradation reaction Methods 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 101710137422 Suppressor of cytokine signaling 2 Proteins 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 102100034531 AP-1 complex subunit mu-2 Human genes 0.000 claims 3
- 101000924636 Homo sapiens AP-1 complex subunit mu-2 Proteins 0.000 claims 3
- 101000944124 Homo sapiens Cingulin Proteins 0.000 claims 3
- 230000000875 corresponding effect Effects 0.000 description 81
- 210000001124 body fluid Anatomy 0.000 description 80
- 239000010839 body fluid Substances 0.000 description 80
- 210000001519 tissue Anatomy 0.000 description 79
- 101710122611 Cingulin Proteins 0.000 description 76
- 102000004169 proteins and genes Human genes 0.000 description 61
- 102100035784 Decorin Human genes 0.000 description 60
- 101001000206 Homo sapiens Decorin Proteins 0.000 description 60
- 239000013615 primer Substances 0.000 description 56
- 239000002987 primer (paints) Substances 0.000 description 56
- 235000018102 proteins Nutrition 0.000 description 49
- 238000002405 diagnostic procedure Methods 0.000 description 36
- 238000003745 diagnosis Methods 0.000 description 33
- 239000000104 diagnostic biomarker Substances 0.000 description 31
- 238000002493 microarray Methods 0.000 description 30
- 230000035945 sensitivity Effects 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 18
- 239000000092 prognostic biomarker Substances 0.000 description 15
- 210000004696 endometrium Anatomy 0.000 description 12
- 230000001105 regulatory effect Effects 0.000 description 11
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 10
- 238000004393 prognosis Methods 0.000 description 10
- 208000002495 Uterine Neoplasms Diseases 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 210000002381 plasma Anatomy 0.000 description 8
- 210000004881 tumor cell Anatomy 0.000 description 8
- 238000001262 western blot Methods 0.000 description 8
- 201000006828 endometrial hyperplasia Diseases 0.000 description 7
- 208000023965 endometrium neoplasm Diseases 0.000 description 7
- 229940011871 estrogen Drugs 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 7
- 239000013641 positive control Substances 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 230000003248 secreting effect Effects 0.000 description 7
- 206010046766 uterine cancer Diseases 0.000 description 7
- 239000012528 membrane Substances 0.000 description 6
- 230000009245 menopause Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 208000037853 Abnormal uterine bleeding Diseases 0.000 description 5
- 102100028843 DNA mismatch repair protein Mlh1 Human genes 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 208000034158 bleeding Diseases 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 230000027758 ovulation cycle Effects 0.000 description 5
- 229960001603 tamoxifen Drugs 0.000 description 5
- 102100027314 Beta-2-microglobulin Human genes 0.000 description 4
- 102100021429 DNA-directed RNA polymerase II subunit RPB1 Human genes 0.000 description 4
- 101710191461 F420-dependent glucose-6-phosphate dehydrogenase Proteins 0.000 description 4
- 102100035172 Glucose-6-phosphate 1-dehydrogenase Human genes 0.000 description 4
- 101710155861 Glucose-6-phosphate 1-dehydrogenase Proteins 0.000 description 4
- 101710174622 Glucose-6-phosphate 1-dehydrogenase, chloroplastic Proteins 0.000 description 4
- 101710137456 Glucose-6-phosphate 1-dehydrogenase, cytoplasmic isoform Proteins 0.000 description 4
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 description 4
- 101000577853 Homo sapiens DNA mismatch repair protein Mlh1 Proteins 0.000 description 4
- 101001106401 Homo sapiens DNA-directed RNA polymerase II subunit RPB1 Proteins 0.000 description 4
- 101000609211 Homo sapiens Polyadenylate-binding protein 2 Proteins 0.000 description 4
- 101000577619 Homo sapiens Profilin-1 Proteins 0.000 description 4
- 102100039427 Polyadenylate-binding protein 2 Human genes 0.000 description 4
- 102100034391 Porphobilinogen deaminase Human genes 0.000 description 4
- 101710189720 Porphobilinogen deaminase Proteins 0.000 description 4
- 101710170827 Porphobilinogen deaminase, chloroplastic Proteins 0.000 description 4
- 101710100896 Probable porphobilinogen deaminase Proteins 0.000 description 4
- 102100028857 Profilin-1 Human genes 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 208000016018 endometrial polyp Diseases 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- CXVGEDCSTKKODG-UHFFFAOYSA-N sulisobenzone Chemical compound C1=C(S(O)(=O)=O)C(OC)=CC(O)=C1C(=O)C1=CC=CC=C1 CXVGEDCSTKKODG-UHFFFAOYSA-N 0.000 description 4
- 238000002604 ultrasonography Methods 0.000 description 4
- 206010046811 uterine polyp Diseases 0.000 description 4
- 210000004291 uterus Anatomy 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 208000008589 Obesity Diseases 0.000 description 3
- 238000001574 biopsy Methods 0.000 description 3
- 210000003756 cervix mucus Anatomy 0.000 description 3
- 239000013068 control sample Substances 0.000 description 3
- 238000010195 expression analysis Methods 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000003821 menstrual periods Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 235000020824 obesity Nutrition 0.000 description 3
- 229920001184 polypeptide Polymers 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 239000000107 tumor biomarker Substances 0.000 description 3
- 235000019737 Animal fat Nutrition 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 2
- 208000017095 Hereditary nonpolyposis colon cancer Diseases 0.000 description 2
- 101000584612 Homo sapiens GTPase KRas Proteins 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100034256 Mucin-1 Human genes 0.000 description 2
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 2
- 208000000450 Pelvic Pain Diseases 0.000 description 2
- 208000006994 Precancerous Conditions Diseases 0.000 description 2
- 102000003946 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 238000003748 differential diagnosis Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 201000003908 endometrial adenocarcinoma Diseases 0.000 description 2
- 208000029382 endometrium adenocarcinoma Diseases 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 230000005906 menstruation Effects 0.000 description 2
- 238000010208 microarray analysis Methods 0.000 description 2
- 230000002611 ovarian Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000002974 pharmacogenomic effect Effects 0.000 description 2
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000002028 premature Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 206010046901 vaginal discharge Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- BXJHWYVXLGLDMZ-UHFFFAOYSA-N 6-O-methylguanine Chemical compound COC1=NC(N)=NC2=C1NC=N2 BXJHWYVXLGLDMZ-UHFFFAOYSA-N 0.000 description 1
- 206010000084 Abdominal pain lower Diseases 0.000 description 1
- 102100028914 Catenin beta-1 Human genes 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 102100022307 DNA polymerase alpha catalytic subunit Human genes 0.000 description 1
- 101710174969 DNA polymerase alpha catalytic subunit Proteins 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 108010024212 E-Selectin Proteins 0.000 description 1
- 102100023471 E-selectin Human genes 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102100034237 Endosome/lysosome-associated apoptosis and autophagy regulator 1 Human genes 0.000 description 1
- 102100023688 Eotaxin Human genes 0.000 description 1
- 101710139422 Eotaxin Proteins 0.000 description 1
- 102100039556 Galectin-4 Human genes 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 101150054472 HER2 gene Proteins 0.000 description 1
- 208000008051 Hereditary Nonpolyposis Colorectal Neoplasms Diseases 0.000 description 1
- 206010051922 Hereditary non-polyposis colorectal cancer syndrome Diseases 0.000 description 1
- 101000916173 Homo sapiens Catenin beta-1 Proteins 0.000 description 1
- 101000925880 Homo sapiens Endosome/lysosome-associated apoptosis and autophagy regulator 1 Proteins 0.000 description 1
- 101000608765 Homo sapiens Galectin-4 Proteins 0.000 description 1
- 101001065663 Homo sapiens Lipolysis-stimulated lipoprotein receptor Proteins 0.000 description 1
- 101710137164 L-proline cis-4-hydroxylase Proteins 0.000 description 1
- 102100032010 Lipolysis-stimulated lipoprotein receptor Human genes 0.000 description 1
- 201000005027 Lynch syndrome Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 108010026664 MutL Protein Homolog 1 Proteins 0.000 description 1
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 description 1
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 description 1
- 206010055870 Postmenopausal haemorrhage Diseases 0.000 description 1
- 208000005107 Premature Birth Diseases 0.000 description 1
- 102000055027 Protein Methyltransferases Human genes 0.000 description 1
- 108700040121 Protein Methyltransferases Proteins 0.000 description 1
- 108010044012 STAT1 Transcription Factor Proteins 0.000 description 1
- 102000004265 STAT2 Transcription Factor Human genes 0.000 description 1
- 108010081691 STAT2 Transcription Factor Proteins 0.000 description 1
- 102100029904 Signal transducer and activator of transcription 1-alpha/beta Human genes 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 description 1
- 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 description 1
- 208000024776 abnormal vaginal bleeding Diseases 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 208000009060 clear cell adenocarcinoma Diseases 0.000 description 1
- 230000002380 cytological effect Effects 0.000 description 1
- 238000012303 cytoplasmic staining Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000010339 dilation Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 108700020302 erbB-2 Genes Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000010255 female reproductive organ cancer Diseases 0.000 description 1
- 210000005002 female reproductive tract Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- RQFCJASXJCIDSX-UUOKFMHZSA-N guanosine 5'-monophosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O RQFCJASXJCIDSX-UUOKFMHZSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 238000002657 hormone replacement therapy Methods 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000009802 hysterectomy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000002175 menstrual effect Effects 0.000 description 1
- 230000033607 mismatch repair Effects 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000000520 progressive familial heart block Diseases 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 102200024044 rs1555523872 Human genes 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 208000004548 serous cystadenocarcinoma Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 238000011272 standard treatment Methods 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000003160 two-hybrid assay Methods 0.000 description 1
- 230000009452 underexpressoin Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57442—Specifically defined cancers of the uterus and endometrial
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
- C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/112—Disease subtyping, staging or classification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/16—Primer sets for multiplex assays
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09166398 | 2009-07-24 | ||
| EP09166398.9 | 2009-07-24 | ||
| PCT/EP2010/004550 WO2011009637A2 (en) | 2009-07-24 | 2010-07-23 | Markers for endometrial cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013500001A JP2013500001A (ja) | 2013-01-07 |
| JP2013500001A5 JP2013500001A5 (enExample) | 2013-09-05 |
| JP5934093B2 true JP5934093B2 (ja) | 2016-06-15 |
Family
ID=42751506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012520964A Expired - Fee Related JP5934093B2 (ja) | 2009-07-24 | 2010-07-23 | 子宮内膜がんのマーカー |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US9046522B2 (enExample) |
| EP (2) | EP2848700B1 (enExample) |
| JP (1) | JP5934093B2 (enExample) |
| KR (1) | KR101828290B1 (enExample) |
| CN (2) | CN105132529A (enExample) |
| AU (1) | AU2010275699B2 (enExample) |
| BR (1) | BR112012001469B1 (enExample) |
| CA (1) | CA2767914C (enExample) |
| DK (1) | DK2456889T3 (enExample) |
| ES (2) | ES2654340T3 (enExample) |
| HR (1) | HRP20141062T1 (enExample) |
| IN (1) | IN2012DN00707A (enExample) |
| MX (1) | MX2012000921A (enExample) |
| PL (1) | PL2456889T3 (enExample) |
| PT (1) | PT2456889E (enExample) |
| RU (1) | RU2596394C2 (enExample) |
| WO (1) | WO2011009637A2 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IN2012DN00707A (enExample) * | 2009-07-24 | 2015-06-19 | Geadic Biotec Aie | |
| WO2013044187A2 (en) * | 2011-09-22 | 2013-03-28 | Memorial Sloan-Kettering Cancer Center | Detecting ovarian cancer |
| EP2787350A1 (en) * | 2013-04-05 | 2014-10-08 | Atlas Antibodies AB | ASRGL1 in endometrial cancer |
| KR102113310B1 (ko) * | 2013-09-03 | 2020-05-20 | 아주대학교 산학협력단 | 암 세포 분리용 조성물, 키트 및 이를 이용한 분리 방법 |
| CA2956723C (en) | 2014-08-12 | 2023-04-11 | Nextgen Jane, Inc. | System and method for monitoring health based on collected bodily fluid |
| ES2897782T3 (es) * | 2014-09-17 | 2022-03-02 | Merck Patent Gmbh | Método de tratamiento de las enfermedades de la metástasis ósea, medicamentos para el tratamiento y método para predecir el resultado clínico del tratamiento de las enfermedades causadas por metástasis ósea |
| CN107102141A (zh) * | 2016-02-23 | 2017-08-29 | 中国科学院生物物理研究所 | 分子标记物cd71及在子宫内膜癌诊断、分期及预后中的应用 |
| EP3442706B1 (en) | 2016-04-13 | 2025-07-23 | NextGen Jane, Inc. | Sample collection and preservation methods |
| JP7240712B2 (ja) * | 2016-05-04 | 2023-03-16 | フンダシオ オスピタル ウニベルシタリ バル デブロン－インスティテュート デ レセルカ | 子宮内膜がんのマーカーとしてのｐｅｒｍ |
| GB201702392D0 (en) * | 2017-02-14 | 2017-03-29 | Univ Edinburgh | Methods for cancer diagnosis using a gene expression signature |
| CN108732351A (zh) * | 2017-04-20 | 2018-11-02 | 中国科学院上海生命科学研究院 | Eps8l2作为指示肝内结节及早期预警肝癌的生物标志物 |
| CN108732349A (zh) * | 2017-04-20 | 2018-11-02 | 中国科学院上海生命科学研究院 | Lta4h作为指示肝内结节及早期预警肝癌的生物标志物 |
| CN108732350A (zh) * | 2017-04-20 | 2018-11-02 | 中国科学院上海生命科学研究院 | Pla2g6作为指示肝内结节及早期预警肝癌的生物标志物 |
| CN109085359A (zh) * | 2017-06-13 | 2018-12-25 | 中国医学科学院肿瘤医院 | 血清蛋白标志物组合在结直肠癌筛查和诊治中的应用 |
| PT3655778T (pt) * | 2017-07-21 | 2023-08-18 | Fundacio Hospital Univ Vall Dhebron Institut De Recerca | Agrin como marcador de cancro do endométrio |
| JP2021526812A (ja) * | 2018-06-13 | 2021-10-11 | ２３イキガイ ピーティーイー リミテッド | 多能性幹細胞バイオマーカーを分析するための方法およびその実施 |
| CN109097462B (zh) * | 2018-09-10 | 2022-01-11 | 青岛市海慈医疗集团 | Ap1m2基因作为诊断青光眼的分子标志物的应用 |
| WO2020130190A1 (ko) * | 2018-12-20 | 2020-06-25 | 경상대학교병원 | 신장암의 발병 위험성 예측 또는 진단을 위한 정보제공방법 |
| EP3914163A4 (en) * | 2019-01-23 | 2022-04-13 | Gina-Life Diagnostics Ltd. | CANCER DIAGNOSTIC AND MONITORING APPARATUS, SYSTEMS AND METHODS |
| CN109797217A (zh) * | 2019-03-27 | 2019-05-24 | 河北医科大学第二医院 | 帕金森生物标志物及其在制备检测产品中的应用 |
| CN109811058B (zh) * | 2019-03-31 | 2021-11-12 | 青岛泱深生物医药有限公司 | 与宫颈疾病发生发展相关的生物标志物及其应用 |
| US20240218454A1 (en) * | 2021-04-22 | 2024-07-04 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Diagnostic to support clinical trial matching and exploratory biomarker analyses in cancer patients |
| CN114317750B (zh) * | 2021-12-29 | 2024-05-14 | 上海市第十人民医院 | 一种卵巢癌生物标志物及其在制备用于卵巢癌腹水转移疾病的药物或试剂盒中的应用 |
| KR102584898B1 (ko) * | 2022-10-24 | 2023-10-04 | 연세대학교 산학협력단 | 자궁내막암 진단 방법 및 이를 이용한 키트 |
| WO2024192014A1 (en) * | 2023-03-12 | 2024-09-19 | Novelna Inc. | Endometrial cancer detection proteins and methods of use thereof |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AUPO573697A0 (en) * | 1997-03-20 | 1997-04-10 | Prince Henry's Institute Of Medical Research | Diagnosis of endometrial cancer |
| US7014996B1 (en) * | 1998-10-02 | 2006-03-21 | Diadexus, Inc. | Method of diagnosing, monitoring, staging, imaging and treating gynecologic cancers |
| AUPQ219799A0 (en) | 1999-08-13 | 1999-09-02 | R. Lurie Pty Ltd | Apparatus for obtaining potological samples |
| US6884578B2 (en) | 2000-03-31 | 2005-04-26 | Affymetrix, Inc. | Genes differentially expressed in secretory versus proliferative endometrium |
| RU2232397C2 (ru) * | 2002-04-03 | 2004-07-10 | НИИ онкологии им. проф. Н.Н. Петрова | Способ ранней диагностики патологических состояний эндометрия |
| US20040063120A1 (en) * | 2002-07-10 | 2004-04-01 | The Regents Of The University Of Michigan | Expression profile of lung cancer |
| WO2004105573A2 (en) * | 2003-05-21 | 2004-12-09 | The Wistar Institute Of Anatomy And Biology | Method of diagnosis of cancer based on gene expression profiles in cells |
| WO2005034978A2 (en) | 2003-10-02 | 2005-04-21 | Xantos Biomedicine Ag | MEDICAL USE OF IKKϵ OR OF INHIBITORS THEREOF |
| JP5629894B2 (ja) | 2004-12-07 | 2014-11-26 | 国立大学法人大阪大学 | 甲状腺乳頭癌を診断するための新規のマーカー |
| EP2295601A1 (en) | 2005-02-10 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| EP2266561A3 (en) * | 2005-09-07 | 2011-05-18 | Merck Serono S.A. | IKK Inhibitors for the Treatment of Endometriosis |
| US20070134687A1 (en) * | 2005-09-12 | 2007-06-14 | Aurelium Biopharma Inc. | Focused microarray and methods of diagnosing cancer |
| CN101384903A (zh) * | 2006-02-09 | 2009-03-11 | 南佛罗里达大学 | 利用bcl-2水平的增高检测癌肿 |
| US20070287158A1 (en) * | 2006-06-09 | 2007-12-13 | George Gorodeski | Cell collection and disease screening |
| EP1978106A1 (en) | 2007-04-07 | 2008-10-08 | Universitätsklinikum Hamburg-Eppendorf | Detection of ESR1 amplification in endometrium cancer and ovary cancer |
| WO2008137591A2 (en) | 2007-05-02 | 2008-11-13 | Biocept, Inc. | Non-invasive detection of endometrial cancer |
| JP5419195B2 (ja) | 2007-08-03 | 2014-02-19 | 国立大学法人愛媛大学 | 頭頸部癌の腫瘍マーカー |
| US20110136123A1 (en) * | 2007-08-15 | 2011-06-09 | Universite De Sherbrooke | Alternative splicing gene variants in cancer |
| US8053198B2 (en) * | 2007-09-14 | 2011-11-08 | Meso Scale Technologies, Llc | Diagnostic methods |
| US20110028344A1 (en) | 2008-04-11 | 2011-02-03 | Expression Pathology, Inc. | Biomarkers for endometrial disease |
| IN2012DN00707A (enExample) * | 2009-07-24 | 2015-06-19 | Geadic Biotec Aie |
-
2010
- 2010-07-23 IN IN707DEN2012 patent/IN2012DN00707A/en unknown
- 2010-07-23 WO PCT/EP2010/004550 patent/WO2011009637A2/en not_active Ceased
- 2010-07-23 EP EP14183077.8A patent/EP2848700B1/en not_active Not-in-force
- 2010-07-23 EP EP10736990.2A patent/EP2456889B1/en active Active
- 2010-07-23 ES ES14183077.8T patent/ES2654340T3/es active Active
- 2010-07-23 MX MX2012000921A patent/MX2012000921A/es active IP Right Grant
- 2010-07-23 RU RU2012106432/10A patent/RU2596394C2/ru active
- 2010-07-23 KR KR1020127004840A patent/KR101828290B1/ko not_active Expired - Fee Related
- 2010-07-23 HR HRP20141062AT patent/HRP20141062T1/hr unknown
- 2010-07-23 PL PL10736990T patent/PL2456889T3/pl unknown
- 2010-07-23 CN CN201510425228.XA patent/CN105132529A/zh active Pending
- 2010-07-23 ES ES10736990.2T patent/ES2523683T3/es active Active
- 2010-07-23 DK DK10736990.2T patent/DK2456889T3/en active
- 2010-07-23 AU AU2010275699A patent/AU2010275699B2/en not_active Ceased
- 2010-07-23 US US13/386,536 patent/US9046522B2/en active Active
- 2010-07-23 CA CA2767914A patent/CA2767914C/en active Active
- 2010-07-23 PT PT107369902T patent/PT2456889E/pt unknown
- 2010-07-23 BR BR112012001469-2A patent/BR112012001469B1/pt not_active IP Right Cessation
- 2010-07-23 JP JP2012520964A patent/JP5934093B2/ja not_active Expired - Fee Related
- 2010-07-23 CN CN201080042678.6A patent/CN102549169B/zh not_active Expired - Fee Related
-
2015
- 2015-06-01 US US14/727,549 patent/US20150337392A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2654340T3 (es) | 2018-02-13 |
| RU2012106432A (ru) | 2013-08-27 |
| CN102549169A (zh) | 2012-07-04 |
| RU2596394C2 (ru) | 2016-09-10 |
| US20120122726A1 (en) | 2012-05-17 |
| EP2456889B1 (en) | 2014-09-03 |
| EP2456889A2 (en) | 2012-05-30 |
| BR112012001469A2 (pt) | 2020-08-11 |
| US9046522B2 (en) | 2015-06-02 |
| HRP20141062T1 (hr) | 2015-01-02 |
| US20150337392A1 (en) | 2015-11-26 |
| CN105132529A (zh) | 2015-12-09 |
| EP2848700A1 (en) | 2015-03-18 |
| CN102549169B (zh) | 2016-02-24 |
| AU2010275699A1 (en) | 2012-02-02 |
| MX2012000921A (es) | 2012-06-12 |
| AU2010275699B2 (en) | 2016-06-16 |
| CA2767914C (en) | 2020-02-25 |
| WO2011009637A3 (en) | 2011-04-14 |
| EP2848700B1 (en) | 2017-10-04 |
| IN2012DN00707A (enExample) | 2015-06-19 |
| JP2013500001A (ja) | 2013-01-07 |
| ES2523683T3 (es) | 2014-11-28 |
| CA2767914A1 (en) | 2011-01-27 |
| BR112012001469B1 (pt) | 2021-08-10 |
| KR20120047334A (ko) | 2012-05-11 |
| PL2456889T3 (pl) | 2015-02-27 |
| PT2456889E (pt) | 2014-11-21 |
| KR101828290B1 (ko) | 2018-02-12 |
| WO2011009637A2 (en) | 2011-01-27 |
| DK2456889T3 (en) | 2014-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5934093B2 (ja) | 子宮内膜がんのマーカー | |
| US11892453B2 (en) | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis | |
| JP6048660B2 (ja) | 甲状腺癌を診断および処置するための方法および組成物 | |
| CN104583422A (zh) | 标志物在诊断和治疗前列腺癌中的用途 | |
| EP3714070B1 (en) | A novel cip2a variant and uses thereof | |
| JP2020201278A (ja) | 癌のバイオマーカーとしてのｐｄ−ｅｃｇｆ | |
| JP2007510424A (ja) | 分子マーカー | |
| US7355025B2 (en) | Marker molecules associated with lung tumors | |
| AU2013328385B2 (en) | Method for the diagnosis, prognosis and treatment of prostate cancer metastasis using c-MAF | |
| JP2007503826A (ja) | 乳癌のリスクの診断 | |
| WO2004072285A1 (en) | “goblin” cancer associated polypeptides, related reagents, and methods of use thereof | |
| JP2007520217A (ja) | 新規ヌクレオチドおよびアミノ酸配列、ならびにそれを用いた乳癌診断のためのアッセイおよび使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130722 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130722 |
|
| RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20140120 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20141118 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150217 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150312 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150413 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150518 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150518 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151110 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160209 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160309 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160405 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160506 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5934093 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |